Demant is well on its way to meeting expectations,” says Jyske Bank analyst Janne Vincent Kjær.
No actionable change — this is a sell-side financial analyst opinion with no clinical or product content.
Positive analyst coverage can reflect and reinforce investor confidence in Demant's portfolio strategy, indirectly signaling stability for the audiologists and dispensers who rely on their products.
- 01Jyske Bank analyst Janne Vincent Kjær rates Demant on track for 2026 targets.
- 02Assessment based on strong fiscal year start, not new product or clinical data.
